JP2002543825A - 造血細胞内分子相互作用 - Google Patents

造血細胞内分子相互作用

Info

Publication number
JP2002543825A
JP2002543825A JP2000618312A JP2000618312A JP2002543825A JP 2002543825 A JP2002543825 A JP 2002543825A JP 2000618312 A JP2000618312 A JP 2000618312A JP 2000618312 A JP2000618312 A JP 2000618312A JP 2002543825 A JP2002543825 A JP 2002543825A
Authority
JP
Japan
Prior art keywords
protein
pdz
cells
peptide
binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2000618312A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002543825A5 (enExample
Inventor
エス． ルー，ピーター
Original Assignee
アーバー ビータ コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アーバー ビータ コーポレイション filed Critical アーバー ビータ コーポレイション
Publication of JP2002543825A publication Critical patent/JP2002543825A/ja
Publication of JP2002543825A5 publication Critical patent/JP2002543825A5/ja
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Transplantation (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2000618312A 1999-05-14 2000-05-12 造血細胞内分子相互作用 Withdrawn JP2002543825A (ja)

Applications Claiming Priority (27)

Application Number Priority Date Filing Date Title
US13411799P 1999-05-14 1999-05-14
US13411899P 1999-05-14 1999-05-14
US13411499P 1999-05-14 1999-05-14
US60/134,118 1999-05-14
US60/134,114 1999-05-14
US60/134,117 1999-05-14
US16086099P 1999-10-21 1999-10-21
US60/160,860 1999-10-21
US16249899P 1999-10-29 1999-10-29
US60/162,498 1999-10-29
US17045399P 1999-12-13 1999-12-13
US60/170,453 1999-12-13
US17619500P 2000-01-14 2000-01-14
US60/176,195 2000-01-14
US18229600P 2000-02-14 2000-02-14
US60/182,296 2000-02-14
US19652800P 2000-04-11 2000-04-11
US19626700P 2000-04-11 2000-04-11
US54727600A 2000-04-11 2000-04-11
US19652700P 2000-04-11 2000-04-11
US19646000P 2000-04-11 2000-04-11
US09/547,276 2000-04-11
US60/196,528 2000-04-11
US60/196,460 2000-04-11
US60/196,527 2000-04-11
US60/196267 2000-04-11
PCT/US2000/013161 WO2000069896A2 (en) 1999-05-14 2000-05-12 Molecular interactions in haematopoietic cells

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2011029100A Division JP2011102326A (ja) 1999-05-14 2011-02-14 造血細胞内分子相互作用

Publications (2)

Publication Number Publication Date
JP2002543825A true JP2002543825A (ja) 2002-12-24
JP2002543825A5 JP2002543825A5 (enExample) 2007-07-05

Family

ID=27584529

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2000618312A Withdrawn JP2002543825A (ja) 1999-05-14 2000-05-12 造血細胞内分子相互作用
JP2011029100A Pending JP2011102326A (ja) 1999-05-14 2011-02-14 造血細胞内分子相互作用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2011029100A Pending JP2011102326A (ja) 1999-05-14 2011-02-14 造血細胞内分子相互作用

Country Status (4)

Country Link
EP (1) EP1178817A2 (enExample)
JP (2) JP2002543825A (enExample)
ES (1) ES2436624T3 (enExample)
WO (2) WO2000069896A2 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007116945A1 (ja) * 2006-04-07 2007-10-18 University Of Tsukuba 移植片対宿主病予知マーカーおよびその利用
JP2008537478A (ja) * 2005-02-24 2008-09-18 ザ・スクリプス・リサーチ・インステイチユート 単離骨髄球様骨髄細胞集団及びそれを用いた治療方法
JP2009503439A (ja) * 2005-07-01 2009-01-29 アルボー ビータ コーポレーション ウイルス感染および細菌感染の診断および処置のための方法および組成物

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1100890A2 (en) 1998-07-27 2001-05-23 Genentech, Inc. Improved transformation efficiency in phage display through modification of a coat protein
US6942981B1 (en) 1999-05-14 2005-09-13 Arbor Vita Corporation Method of determining interactions with PDZ-domain polypeptides
US20030049695A1 (en) * 2001-02-16 2003-03-13 Lu Peter S. PDZ domain interactions and lipid rafts
US7510824B2 (en) 1999-06-02 2009-03-31 Nono Inc. Method of screening peptides useful in treating traumatic injury to the brain or spinal cord
US7595297B2 (en) 1999-06-02 2009-09-29 Michael Tymianski Method of reducing injury to mammalian cells
WO2002031512A2 (en) * 2000-10-13 2002-04-18 Arbor Vita Corporation Molecular interactions in hematopoietic cells
CA2445309A1 (en) * 2001-04-24 2002-11-07 Otsuka Pharmaceutical Co., Ltd. Crohn's disease antibody-binding peptide and method of examining crohn's disease
AU2011211347B2 (en) * 2001-05-07 2015-02-19 Agriculture Victoria Services Pty Ltd Modification of plant and seed development and plant responses to stresses and stimuli (3)
DE10124342A1 (de) * 2001-05-18 2002-11-28 Biotecon Diagnostics Gmbh Verfahren zum Nachweis von Mikroorganismen der Spezies Yersinia pestis/Yersinia pseudotuberculosis und/oder zur Differzierung zwischen Yersinia pestis und Yersinia pseudotuberculosis
EP1493028A4 (en) * 2001-07-06 2006-06-14 Genentech Inc PHAGEN DISPLAY PRESENTED LIGANDS OF THE PDZ DOMAIN
AU2003291558B2 (en) * 2001-08-03 2009-08-13 Arbor Vita Corporation Molecular interactions in neurons
AU2002321903A1 (en) * 2001-08-03 2003-02-24 Arbor Vita Corporation Molecular interactions in cells
JP2003199459A (ja) 2002-01-07 2003-07-15 Japan Science & Technology Corp リンパ球遊走制御機能欠失モデル非ヒト動物
EP2289535B8 (en) 2004-12-21 2018-08-08 MUSC Foundation for Research Development Compositions and methods for promoting wound healing and tissue regeneration
AU2012202117B2 (en) * 2004-12-21 2014-06-26 Musc Foundation For Research Development Compositions and methods for promoting wound healing and tissue regeneration
US9408381B2 (en) 2004-12-21 2016-08-09 Musc Foundation For Research Development Alpha Connexin c-Terminal (ACT) peptides for use in transplant
WO2007071448A2 (en) * 2005-12-23 2007-06-28 Partnership & Corp. Technology Transfer Synthetic peptides for use as inhibitors of neurotransmitter secretion and as inducers of muscle relaxation
RU2657535C2 (ru) 2012-03-01 2018-06-14 Ферстстринг Рисерч, Инк. Гели для местного применения, содержащие с-концевые пептиды альфа-коннексина (act)
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
KR20200003160A (ko) * 2017-05-03 2020-01-08 바이오마린 파머수티컬 인크. 조혈모세포의 형질도입을 위한 개선된 렌티바이러스
AU2019403393A1 (en) * 2018-12-20 2021-08-05 The University Of Chicago Methods and compositions related to therapeutic peptides for cancer therapy
CA3196342A1 (en) 2020-10-22 2022-04-28 Gautam Ghatnekar Peptide formulations and ophthalmic uses thereof
CN114457005B (zh) * 2022-01-12 2024-03-26 佛山市妇幼保健院 一种小儿尿道平滑肌细胞的分离纯化方法
WO2024199407A1 (en) * 2023-03-31 2024-10-03 Qihan Hong Kong Limited Cancer immunotherapies using engineered cells

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005347A1 (en) * 1996-07-22 1998-02-12 The Trustees Of Columbia University In The City Of New York Compounds that inhibit interaction between signal-transducing proteins and the glgf (pdz/dhr) domain and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998005347A1 (en) * 1996-07-22 1998-02-12 The Trustees Of Columbia University In The City Of New York Compounds that inhibit interaction between signal-transducing proteins and the glgf (pdz/dhr) domain and uses thereof

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008537478A (ja) * 2005-02-24 2008-09-18 ザ・スクリプス・リサーチ・インステイチユート 単離骨髄球様骨髄細胞集団及びそれを用いた治療方法
JP2009503439A (ja) * 2005-07-01 2009-01-29 アルボー ビータ コーポレーション ウイルス感染および細菌感染の診断および処置のための方法および組成物
WO2007116945A1 (ja) * 2006-04-07 2007-10-18 University Of Tsukuba 移植片対宿主病予知マーカーおよびその利用
JP5296530B2 (ja) * 2006-04-07 2013-09-25 国立大学法人 筑波大学 移植片対宿主病予知マーカーおよびその利用

Also Published As

Publication number Publication date
WO2000069897A2 (en) 2000-11-23
ES2436624T3 (es) 2014-01-03
WO2000069897A3 (en) 2001-11-08
WO2000069896A9 (en) 2002-10-03
WO2000069896A2 (en) 2000-11-23
EP1178817A2 (en) 2002-02-13
WO2000069896A3 (en) 2001-07-05
JP2011102326A (ja) 2011-05-26
WO2000069897A9 (en) 2002-07-04

Similar Documents

Publication Publication Date Title
JP2011102326A (ja) 造血細胞内分子相互作用
US20090149339A1 (en) Methods of Identifying Modulators of Interaction Between PDZ Domain Proteins and PL Proteins
US20120093873A1 (en) Molecular Interactions in Hematopoietic Cells
US7858322B2 (en) Method of determining inhibition of binding to TRPM7 protein
WO2002042422A2 (en) Molecular interactions in hematopoietic cells
US20090075377A1 (en) Molecular interactions in cells
US20110039758A1 (en) Molecular Interactions in Neurons
EP1443951A2 (en) Molecular interactions in cells
US20050019841A1 (en) Modulation of signaling pathways
EP1578365A2 (en) Molecular interactions in neurons
US20020169283A1 (en) Clasp-7 transmembrane protein
CA2350086A1 (en) Methods for preventing cardiac hypertrophy and heart failure by inhibition of mef2 transcription factor
US20050282743A1 (en) Molecular interactions in cells
WO2002031512A2 (en) Molecular interactions in hematopoietic cells
JP2001523455A (ja) Ｃｄｋ２タンパク質およびｃｄｋ２タンパク質複合体
EP2385124B1 (en) Peptides or peptide analogues for modulating the binding of a PDZ protein and a PL protein
US7256279B2 (en) Protein having ribonucleotide reductase activity and DNA thereof
US7919584B1 (en) Methods and compositions for diagnosis and treatment of asthma
US20020086382A1 (en) Clasp-3 transmembrane protein
US20060264610A1 (en) Protein complexes of the tip60 transcriptional activator protein
US20030103992A1 (en) Clasp membrane proteins
WO2001042297A9 (en) Clasp-3 transmembrane protein
WO2001085908A2 (en) Clasp-1 transmembrane protein

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070511

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070511

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100202

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100506

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100513

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101012

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110214

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20110418

A761 Written withdrawal of application

Free format text: JAPANESE INTERMEDIATE CODE: A761

Effective date: 20110422